{
    "id": 30691,
    "fullName": "PDGFRA D846V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PDGFRA D846V lies within the protein kinase domain of the Pdgfra protein (UniProt.org). D846V is associated with resistance to Gleevec (imatinib) (PMID: 16624552), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 15932,
                    "pubMedId": 16624552,
                    "title": "KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16624552"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5156,
        "geneSymbol": "PDGFRA",
        "terms": [
            "PDGFRA",
            "CD140A",
            "PDGFR-2",
            "PDGFR2"
        ]
    },
    "variant": "D846V",
    "createDate": "08/07/2019",
    "updateDate": "03/02/2020",
    "referenceTranscriptCoordinates": {
        "id": 181863,
        "transcript": "NM_006206",
        "gDna": "chr4:g.54285938A>T",
        "cDna": "c.2537A>T",
        "protein": "p.D846V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17962,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, none of 4 gastrointestinal stromal tumor patients harboring PDGFRA D842V (n=3) or PDGFRA D846V (n=1) mutations treated on a Phase III clinical trial demonstrated a response to treatment with Gleevec (imatinib), compared to 5 of 6 patients harboring PDGFRA sensitizing mutations (PMID: 16624552).",
            "molecularProfile": {
                "id": 32920,
                "profileName": "PDGFRA D846V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15932,
                    "pubMedId": 16624552,
                    "title": "KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16624552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17961,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient with metastatic osteosarcoma demonstrated a partial response to treatment with Nexavar (sorafenib) for 51 months prior to recurrence, and analysis of the pre-progression tumor demonstrated presence of PDGFRA D846V, which was not present in the post-progression sample, suggesting that the PDGFRA variant may have conferred sensitivity to Nexavar (sorafenib) (PMID: 30318721).",
            "molecularProfile": {
                "id": 32920,
                "profileName": "PDGFRA D846V"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15694,
                    "pubMedId": 30318721,
                    "title": "Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30318721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32920,
            "profileName": "PDGFRA D846V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 181863,
            "transcript": "NM_006206",
            "gDna": "chr4:g.54285938A>T",
            "cDna": "c.2537A>T",
            "protein": "p.D846V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 181864,
            "transcript": "XM_005265743",
            "gDna": "chr4:g.54285938A>T",
            "cDna": "c.2537A>T",
            "protein": "p.D846V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 181865,
            "transcript": "XM_011534385",
            "gDna": "chr4:g.54285938A>T",
            "cDna": "c.2537A>T",
            "protein": "p.D846V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}